Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy

Delayed and sequencial hemolytic uremic syndrome as a complication of Gemcitabine therapy

Gemcitabine is a widely used drug in the treatment of diverse malignancies and its use has been approved by the US Food and Drug Administration. This drug has been associated with a rare adverse event, the Hemolytic Uremic Syndrome (HUS), characterized by acute kidney injury, microangiopathic hemoly...

Full description

Bibliographic Details
Main Authors: Thaís Sampaio Corrêa de Almeida, Renata Colombo Bonadio, Rafaela Lopes da Silva Naves, Paulo Henrique Amor-Divino, Paulo Marcelo Gehm Hoff
Format: Article
Language:English
Published: Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia 2022-12-01
Series:Brazilian Journal of Oncology
Subjects:
pancreatic neoplasms
hemolytic-uremic syndrome
drug therapy
Online Access:https://www.brazilianjournalofoncology.com.br/details/217/en-US/delayed-and-sequencial-hemolytic-uremic-syndrome-as-a-complication-of-gemcitabine-therapy

Internet

https://www.brazilianjournalofoncology.com.br/details/217/en-US/delayed-and-sequencial-hemolytic-uremic-syndrome-as-a-complication-of-gemcitabine-therapy

Similar Items